Skin Models pp 355-357 | Cite as

High Doses of Antigen-Nonspecific IgG do not Inhibit Pemphigus Acantholysis in Skin Organ Cultures

  • TH Hunziker
  • U. E. Nydegger
  • P. J. Späth
  • H. A. Gerber
  • M. Hess
  • U. Wiesmann
Conference paper

Abstract

A patient suffering from severe pemphigus vulgaris was treated by large volume plasma exchange in combination with an immunosuppressive regimen (corticosteroids and azathioprine [2]. In addition, she was given high doses of polyclonal, polyspecific human IgG (0.5 g Sandoglobulin/kg, Table 1) through the i.v. route (IGIV) at the end of each plasma exchange session to restore depleted humoral antibodies and thus reduce the danger of infections. Recent reports show evidence that IGIV protect target plateles in idiopathic thrombocytopenic purpura from attack by anti-plateled auto-antibodies and/or immune complexes [3, 6] and therefore we hoped that this therapeutic measure might yield additional benefits, such as nonspecific displacement of the autoantibody from its epidermal target (“coating” of the antigen) [1], or blocking of anti-epidermal autoantibodies by complex formation with so called public antiidiotypes present in IGIV [4].

Keywords

Saccharose Albumin Corticosteroid Penicillin Streptomycin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gross B, Haessig A, Luescher EF, Nydegger UE, (1983) Monomeric IgG preparations for intravenous use inhibit platelet stimulation by polymeric IgG. Brit J Haematol 53: 289–299CrossRefGoogle Scholar
  2. 2.
    Hunziker Th, Schwarzenbach HR, Krebs A, Nydegger UE, Camponovo F, Hess M (1981) Plasmaaustausch bei Pemphigus vulgaris. Schweiz Med Wschr 111: 1637–1642PubMedGoogle Scholar
  3. 3.
    Imbach P, d’Apuzzo V, Hirt A, Rossi E, Vest M, Barandun S, Baumgartner C, Morell A, Schöni M, Wagner HP (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet I: 1228–1231PubMedCrossRefGoogle Scholar
  4. 4.
    Lambert PH (ed) (1983) Immunopathology of idiotypic interactions. No 1, Vol 6 of Springer Sem in ImmunopatholGoogle Scholar
  5. 5.
    Liehl E, Armerding D, Böckmann J (1980) Effektorfunktionen und protektive Wirkung von Standardimmunglobulin und Immunglobulin nach modifizierter milder Säurebehandlung. Infection 8: 194–198CrossRefGoogle Scholar
  6. 6.
    Nydegger UE, Imbach P, Grau GE. Prospects for therapy of autoimmune disease with immunoglobulins prepared for intravenous use. In: Lambert PH, Izui S, Perrin LH (eds). Recent advances in SLE. Academic Press, London (in press)Google Scholar
  7. 7.
    Römer J, Morgenthaler JJ, Scherz R, Skvaril F (1982) Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content. Vox Sang 42: 62–73PubMedGoogle Scholar
  8. 8.
    Römer J, Späth PJ, Skvaril F, Nydegger UE (1982) Characterization of various immunoglobulin preparations for intravenous application. II. Complement activation and binding to staphylococcus protein A. Vox Sang 42: 74–80PubMedGoogle Scholar
  9. 9.
    Sarkany I, Grice K, Caron GA (1965) Organ culture of adult human skin. Brit J Dermatol 77: 65–76CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • TH Hunziker
  • U. E. Nydegger
  • P. J. Späth
  • H. A. Gerber
  • M. Hess
  • U. Wiesmann

There are no affiliations available

Personalised recommendations